Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07924644
NA

AI-Based Digital Pathology Model for Predicting Treatment Response and Prognosis in mHSPC

Sponsor: Xiangya Hospital of Central South University

View on ClinicalTrials.gov

Summary

The goal of this multicenter observational study is to develop and validate an artificial intelligence-based digital pathology model to predict treatment response and prognosis in adult men with metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy plus androgen receptor signaling inhibitors. The main questions it aims to answer are: Can digital pathology-based artificial intelligence predict deep prostate-specific antigen response, defined as prostate-specific antigen less than 0.2 ng/mL at 6 to 7 months after treatment? Can digital pathology-based artificial intelligence predict progression to metastatic castration-resistant prostate cancer and time to metastatic castration-resistant prostate cancer? Researchers will compare artificial intelligence-defined low-risk and high-risk groups to evaluate whether the model can improve prediction of treatment response and prognosis beyond conventional clinicopathological risk stratification. Participants will not receive any additional intervention as part of this study. Researchers will retrospectively collect clinical characteristics, treatment records, prostate-specific antigen response data, follow-up outcomes, and archived prostate biopsy slides from participating centers. The biopsy slides will be scanned into whole-slide images and analyzed using artificial intelligence to develop and validate predictive models.

Official title: A Multicenter Study on the Development and Validation of an Artificial Intelligence-Based Digital Pathology Model for Predicting Treatment Response and Prognosis in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1115

Start Date

2019-01-01

Completion Date

2026-12-31

Last Updated

2026-11-09

Healthy Volunteers

No

Interventions

OTHER

Artificial Intelligence-Based Digital Pathology Assessment

Archived prostate biopsy pathology slides will be digitized as whole-slide images and analyzed using an artificial intelligence-based digital pathology model. The model will be developed and validated to predict treatment response and prognosis in patients with metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy plus androgen receptor signaling inhibitors. No study-mandated treatment intervention will be assigned, and the artificial intelligence results will not be used to guide clinical treatment decisions during this observational study.

Locations (1)

Xiangya Hospital Central South University

Changsha, Hunan, China